Please assess the completion status of the following clinical trial:

Trial Title: Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed adenocarcinoma of the pancreas~2. Patients is a candidate for gemcitabine chemotherapy (adjuvant, metastatic, locally advanced, borderline resectable settings all permitted)~3. Patients at least 18 years of age~4. ECOG performance status 0-2~5. Consent to donate 12 tubes of peripheral blood of 10 mL each~6. Adequate organ function as defined as -neutrophil count ≥ 1200 -platelets ≥ 75,000 -hemoglobin ≥ 8.0 -bilirubin ≤ 2.0 -creatinine ≤2.0 or calculated GFR ≥ 30~7. Ability to understand and willingness to sign a written informed consent document~8. Prior chemotherapy permitted, as long as 60 days have lapsed since last dose. Prior radiation therapy permitted, as long as 28 days lapsed since last treatment.~9. Patients may receive other concurrent chemotherapy, immunotherapy, or radiotherapy~Exclusion Criteria:~1. Patients never been immunized with tetanus toxoid (TT). Patients with a history of adverse reaction to tetanus vaccine (with the exception of self-limited fever or local tissue reaction~2. Patients may not be receiving any investigational agents~3. Pregnant women~4. Patients with HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Gemcitabine with TT vaccine booster (Type: EXPERIMENTAL): Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT

Based on this trial design, predict the completion outcome and termination type (if applicable).